Navigation Links
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview
Date:3/12/2008

SAN DIEGO, March 12 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the quarter and year ended December 31, 2007, and provided corporate and clinical program overviews for the year ended 2007 and for 2008 to date.

"During 2007, we continued to advance the Phase III clinical programs for our two product candidates, Acetavance(TM), an intravenous formulation of acetaminophen for the treatment of pain and fever, and Omigard(TM), a topical antimicrobial gel for the prevention of catheter-related infections", stated Ted Schroeder, President and CEO of Cadence Pharmaceuticals. "In addition, we achieved important corporate objectives of strengthening our management team and, in February 2008, raising gross proceeds of approximately $49.3 million in a registered direct equity offering. We believe we now have sufficient resources and capital to advance our two product candidates through to NDA submissions, currently anticipated in the first half of 2009."

Financial Results

For the fourth quarter ended December 31, 2007, Cadence reported a net loss of $14.2 million, or $0.50 per share, compared to a net loss of $9.0 million, or $0.53 per share, for the same period in 2006. For the year ended December 31, 2007, Cadence reported a net loss of $51.7 million, or $1.81 per share, as compared to a net loss of $52.2 million, or $10.07 per share, for the same period in 2006. The results for the year ended December 31, 2007, included approximately $4.3 million in stock-based compensation expense.

As of December 3
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
2. Cadence Pharmaceuticals Chief Medical Officer James Breitmeyer to Present at JMP Securities Healthcare Focus Conference
3. ISTA Pharmaceuticals to Present at the Cowen & Company 28th Annual Health Care Conference
4. SGX Pharmaceuticals Announces Fourth Quarter and Full Year Financial Results
5. Onyx Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference
6. Idenix Pharmaceuticals to Present at the Eleventh Annual Lehman Brothers Global Healthcare Conference
7. Drinking Water Association Discusses Pharmaceuticals in Water
8. Genesis Pharmaceuticals Changes Auditors
9. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
10. Statement from American Water Works Association on Associated Press Story on Pharmaceuticals in Drinking Water
11. Vion Pharmaceuticals Regains NASDAQ Listing Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Today, Therapy Changes announces the start of their Teen ... help increase their knowledge and ability to cope with life’s ... to make healthy and positive decisions while connecting with like-minded ... but also a time of major life transition and stress,” ... . , “Teens can at times feel misunderstood, so rather ...
(Date:7/22/2014)... Quebec (PRWEB) July 22, 2014 ... is a set of simple tools, designed to help ... have little or no experience with biofeedback. The tools ... stressful situations and elucidate any abnormal patterns to teach ... today’s fast paced world, we are familiar with stress ...
(Date:7/22/2014)... Mass. (PRWEB) July 22, 2014 ... EBSCO Information Services , announces the launch ... assist occupational health and safety professionals employed by ... chemicals and need to manage the impact of ... PoisonEXPERT provides access to relevant chemical-specific information and ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 The Muscular Dystrophy ... the third annual MUSCLE UP campaign that will ... more than one million Americans fighting muscle disease. ... to visit participating Jiffy Lube service centers through Sept. 1, ... to continue to make progress in the fight for muscle ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Brand ... landed MediaSource as a Ragan Communications 2014 Health ... will be the second consecutive year that MediaSource placed ... which was awarded to the winning MediaSource team last ... to keep this title against three other contenders that ...
Breaking Medicine News(10 mins):Health News:Therapy Changes Announces Teen Support Group Therapy 2Health News:Thought Technology to Present Software for Stress Control at the 2014 American Psychological Association Convention in DC 2Health News:Thought Technology to Present Software for Stress Control at the 2014 American Psychological Association Convention in DC 3Health News:PoisonEXPERT™ from ExPub Now Available 2Health News:PoisonEXPERT™ from ExPub Now Available 3Health News:Jiffy Lube® Supports Fight Against Muscle Disease with Third Annual MUSCLE UP® Campaign 2Health News:Jiffy Lube® Supports Fight Against Muscle Disease with Third Annual MUSCLE UP® Campaign 3Health News:MediaSource Brand Journalism Returns to Best Health Care Agency Competition in Ragan Communications Health Care Awards 2Health News:MediaSource Brand Journalism Returns to Best Health Care Agency Competition in Ragan Communications Health Care Awards 3
... to Serve Elective Cash Pay ... ... financial services for elective (cash pay) surgery, today,announced a leap forward in ... for bariatric surgeons, cash pay business.,Beginning July 1st, 2008, the BLISCare(SM) insurance ...
... chemotherapeutic agents remains a large problem. In some cases, ... cellular process known as translation, which is central to ... Pelletier and colleagues, at McGill University, Montreal, have identified ... cancer cells to standard anticancer chemotherapeutic agents. , In ...
... a healthier life, study finds , , THURSDAY, June 12 ... aging, a new study found. , Researchers at the ... 60 and older for use of sleeping aids, daytime ... quality, and sleep duration. Based on the results, 20.8 ...
... FDA on food safety , , THURSDAY, June 12 (HealthDay ... ongoing outbreak of salmonella-contaminated tomatoes has risen to 228 ... reported Thursday. , Also Thursday, Congressional investigators said the ... its own stated goals of protecting the nation,s food ...
... Pa., June 12 MEDRAD, INC., has ... PETNET Solutions,a fully owned subsidiary of Siemens ... health care providers to inject Fluorodeoxyglucose,(FDG) for ... an innovative, new way. The partnership will ...
... of Excellence (CCE), the,nation,s only practice-owned and physician ... slate and Board of Directors.,Effective immediately, J. Ike ... the interim President of CCE. In addition, Linda,Bosserman, ... Medical,Officer. Dr. Bosserman had previously served as CCE,s ...
Cached Medicine News:Health News:BLIS to Offer Coverage Through 'A' Rated Insurance Carrier 2Health News:BLIS to Offer Coverage Through 'A' Rated Insurance Carrier 3Health News:Better Sleepers Are 'Successful Agers' 2Health News:228 People in 22 States Sickened in Ongoing Salmonella-Tomato Outbreak 2Health News:228 People in 22 States Sickened in Ongoing Salmonella-Tomato Outbreak 3Health News:228 People in 22 States Sickened in Ongoing Salmonella-Tomato Outbreak 4Health News:228 People in 22 States Sickened in Ongoing Salmonella-Tomato Outbreak 5Health News:MEDRAD and PETNET Solutions Partner for Innovative FDG Delivery 2Health News:MEDRAD and PETNET Solutions Partner for Innovative FDG Delivery 3Health News:Cancer Clinics of Excellence (CCE) Announces Management and Board of Directors Slate at 1st Annual General Membership Meeting 2
(Date:7/22/2014)... , July 22, 2014 The steady ... is spreading to previously rep-friendly specialties, according to ... and marketing consulting firm ZS Associates.      ... 200 U.S. pharmaceutical sales teams. The report examines ... meet with the pharmaceutical sales reps who visit ...
(Date:7/22/2014)... 22, 2014 BioDelivery Sciences International, Inc. (BDSI) ... of Directors has appointed Charles J. (Chuck) Bramlage ... members of the Board.  Mr. Bramlage ... in marketing, sales and other commercial functions.  He is ... a development stage company that was recently acquired by ...
(Date:7/22/2014)... 22, 2014  UL (Underwriters Laboratories), a global ... Food and Drug Administration (FDA) has recognized two ... medical devices incorporating lithium or nickel-based batteries. The ... Household and Commercial Batteries, and UL 1642 - ... Consensus standards are standards recognized by the FDA ...
Breaking Medicine Technology:Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 2Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 3Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 4Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 5BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 2BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 3BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 4BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 5BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 6BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 7Two UL Battery Safety Standards Are now FDA Recognized Consensus Standards for Medical Devices 2
... , RYE, N.Y., Oct. 14 Curemark, LLC, a drug ... diseases, announced that it has enrolled the first patients in ... The first clinical trial patients have been enrolled at Lake ... trial sites with a total 170 children across the country. ...
... Inc. (Nasdaq: VSCP ), a leading provider of quantitative ... the company,s chief business and financial officer, will be presenting ... Bio Investor Forum in San Francisco, California. Ms. Henderson is ... October 29, 2009 at the Palace Hotel, San Francisco. , ...
Cached Medicine Technology:Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment 2VirtualScopics to Present at the 8th Annual Bio Investor Forum 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: